PriceTargets.com logo

Milestone Pharmaceuticals - MIST Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 700.00%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.50 As of 10/4/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for MIST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Milestone Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MIST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MIST

Analyst Price Target is $12.00
▲ +700.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Milestone Pharmaceuticals in the last 3 months. The average price target is $12.00, with a high forecast of $25.00 and a low forecast of $5.00. The average price target represents a 700.00% upside from the last price of $1.50.

This chart shows the closing price for MIST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Milestone Pharmaceuticals. This rating has held steady since June 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/13/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
8/22/2024Rodman & RenshawInitiated CoverageBuy$9.00
7/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00
3/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00
3/5/2024Piper SandlerLower TargetOverweight ➝ Overweight$6.00 ➝ $5.00
2/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00
12/27/2023TD CowenLower TargetOutperform ➝ Outperform$17.00 ➝ $9.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00
6/20/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$8.00 ➝ $4.00
4/12/2023OppenheimerLower TargetOutperform$16.00 ➝ $13.00
3/30/2023HC WainwrightReiterated RatingBuy$25.00
3/9/2023HC WainwrightReiterated RatingBuy$25.00
11/14/2022HC WainwrightBoost TargetBuy$20.00 ➝ $25.00
4/21/2022Piper SandlerUpgradeNeutral ➝ Overweight$8.00 ➝ $10.00
3/29/2022HC WainwrightReiterated RatingBuy
3/5/2021HC WainwrightInitiated CoverageBuy$20.00
7/29/2020OppenheimerUpgradeMarket Perform ➝ Outperform$18.00
7/24/2020Jefferies Financial GroupUpgradeHold ➝ Buy$3.00 ➝ $15.00
7/23/2020CowenBoost TargetOutperform$6.00 ➝ $12.00
7/23/2020Piper SandlerBoost TargetNeutral$3.00 ➝ $8.00
5/14/2020OppenheimerReiterated RatingHold
3/24/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$28.00 ➝ $3.00
3/24/2020OppenheimerDowngradeOutperform ➝ Market Perform
3/24/2020Piper SandlerDowngradeOverweight ➝ Neutral$26.50 ➝ $3.00
3/6/2020Piper SandlerReiterated RatingBuy$26.50
3/6/2020OppenheimerReiterated RatingBuy$32.00
2/21/2020CowenReiterated RatingBuy$32.00
2/4/2020Piper SandlerReiterated RatingBuy$26.50
11/14/2019CowenReiterated RatingBuy$32.00
(Data available from 10/4/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/8/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/7/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Milestone Pharmaceuticals logo
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Read More

Today's Range

Now: $1.50
Low: $1.50
High: $1.55

50 Day Range

MA: $1.45
Low: $1.30
High: $1.55

52 Week Range

Now: $1.50
Low: $1.12
High: $3.52

Volume

99,275 shs

Average Volume

206,631 shs

Market Capitalization

$79.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Milestone Pharmaceuticals?

The following equities research analysts have issued stock ratings on Milestone Pharmaceuticals in the last twelve months: HC Wainwright, Piper Sandler, Rodman & Renshaw, and TD Cowen.
View the latest analyst ratings for MIST.

What is the current price target for Milestone Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Milestone Pharmaceuticals in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 700.0%. HC Wainwright has the highest price target set, predicting MIST will reach $25.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $5.00 for Milestone Pharmaceuticals in the next year.
View the latest price targets for MIST.

What is the current consensus analyst rating for Milestone Pharmaceuticals?

Milestone Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MIST will outperform the market and that investors should add to their positions of Milestone Pharmaceuticals.
View the latest ratings for MIST.

What other companies compete with Milestone Pharmaceuticals?

Other companies that are similar to Milestone Pharmaceuticals include Veru, Strongbridge Biopharma, Sol-Gel Technologies, Corvus Pharmaceuticals and Voyager Therapeutics. Learn More about companies similar to Milestone Pharmaceuticals.

How do I contact Milestone Pharmaceuticals' investor relations team?

Milestone Pharmaceuticals' physical mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company's listed phone number is (514) 336-0444 and its investor relations email address is [email protected]. The official website for Milestone Pharmaceuticals is www.milestonepharma.com. Learn More about contacing Milestone Pharmaceuticals investor relations.